Literature DB >> 2456214

Glycosylation of four acute-phase glycoproteins secreted by rat liver cells in vivo and in vitro. Effects of inflammation and dexamethasone.

O Pos1, W van Dijk, N Ladiges, C Linthorst, M Sala, D van Tiel, W Boers.   

Abstract

We have studied the role of the liver in the relative increase of Concanavalin A (Con A)-reactive molecular forms of various positive rat acute-phase glycoproteins (APGPs) occurring in serum during inflammation. Secretion media of hepatocytes isolated from inflamed rats showed a 2 to 5-fold increase of the total amounts of four APGPs studied in comparison to secretion media of control hepatocytes. These changes were in analogy with those observed for corresponding sera, except for alpha 1-antitrypsin. All the different Con A-reactive molecular forms were present in the media, with exception of the most reactive form of ceruloplasmin. In vitro and in vivo, dexamethasone augmented the secretion of three APGPs, and especially of the Con A-most reactive forms. The in vitro effect of dexamethasone--augmented secretion of Con A-reactive molecular forms of alpha 1-acid glycoprotein and haptoglobin--was comparable with the results obtained for hepatocytes isolated from inflamed rats. In vivo, dexamethasone treatment resulted in an even higher increase of the serum concentration of the Con A-most reactive forms of both APGPs than experimental inflammation did. Although an extrahepatic contribution cannot be excluded, these results suggest that alterations in the Con A reactivity of APGPs as observed during the acute-phase of inflammation have their origin in the liver. A change in the Con A reactivity of glycoprotein indicates a modulation of its glycosylation. Since dexamethasone can affect these changes in vivo and in vitro, glucocorticoids most probably are involved in the regulation of the glycosylation of the APGPs during biosynthesis in the liver.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2456214

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  9 in total

1.  Variation of alpha 1-antitrypsin glycoprotein microheterogeneity in hepatic postresuscitation disease.

Authors:  K Heyne; F K Tegtmeyer; S Weidinger
Journal:  Eur J Pediatr       Date:  1990-08       Impact factor: 3.183

2.  Analysis of the five glycosylation sites of human alpha 1-acid glycoprotein.

Authors:  M J Treuheit; C E Costello; H B Halsall
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

3.  Inflammation-induced changes in expression and glycosylation of genetic variants of alpha 1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic mice.

Authors:  W van Dijk; O Pos; M E van der Stelt; H J Moshage; S H Yap; L Dente; P Baumann; C B Eap
Journal:  Biochem J       Date:  1991-06-01       Impact factor: 3.857

4.  Changes in the serum concentration and the glycosylation of human alpha 1-acid glycoprotein and alpha 1-protease inhibitor in severely burned persons: relation to interleukin-6 levels.

Authors:  O Pos; M E van der Stelt; G J Wolbink; M W Nijsten; G L van der Tempel; W van Dijk
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

5.  Variations in the rate of secretion of different glycosylated forms of rat alpha 1-acid glycoprotein.

Authors:  A Drechou; J D Rouzeau; J Feger; G Durand
Journal:  Biochem J       Date:  1989-11-01       Impact factor: 3.857

Review 6.  Alpha 1-acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function.

Authors:  W van Dijk; E C Havenaar; E C Brinkman-van der Linden
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

7.  Effects of monocytic products, recombinant interleukin-1, and recombinant interleukin-6 on glycosylation of alpha 1-acid glycoprotein: studies with primary human hepatocyte cultures and rats.

Authors:  O Pos; H J Moshage; S H Yap; J P Snieders; L A Aarden; J van Gool; W Boers; A M Brugman; W van Dijk
Journal:  Inflammation       Date:  1989-08       Impact factor: 4.092

8.  Glycosylation of FcgammaRIII in N163 as mechanism of regulating receptor affinity.

Authors:  Bettina Drescher; Torsten Witte; Reinhold E Schmidt
Journal:  Immunology       Date:  2003-11       Impact factor: 7.397

9.  Changes in serum glycoprotein glycosylation during experimental inflammation in mice are general, unrelated to protein type, and opposite changes in man and rat: studies on mouse serum alpha 1-acid glycoprotein, alpha 1-esterase, and alpha 1-protease inhibitor.

Authors:  P M Heegaard
Journal:  Inflammation       Date:  1992-12       Impact factor: 4.092

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.